Opioid detox at Jintara is medically supervised, not a three-day quick fix.

Opioid detox is the medically supervised process of clearing opioids from the body safely. The misconception that this takes three days comes from marketing, not medicine. For most people with opioid use disorder, acute withdrawal alone spans two to four weeks, depending on the opioid, the dose, and how long it has been used.

Many people arrive expecting a rapid three-day detox. The clinical reality is different. The length of an opioid taper is set by the medical team for each person, based on the substance, the dose, and how long it has been used. For fentanyl and other long-acting opioids, the timeline is longer still.

According to NIDA's opioid research overview, opioid use disorder is a chronic, relapsing condition. The acute withdrawal phase alone spans weeks for most people presenting to treatment, not days. The purpose of medically supervised detox is not to accelerate withdrawal beyond what the body can safely manage. It is to keep withdrawal within a tolerable range, monitor for complications, and adjust medications in response to what is actually happening, not what was predicted.

Opioid withdrawal follows a characteristic delayed-peak pattern that catches most people off guard. The first 24 to 48 hours often feel manageable, sometimes even less uncomfortable than expected. Days four to seven bring the full intensity of physical symptoms: muscle aches, sweating, insomnia, diarrhea, nausea, anxiety, and a restlessness that makes sitting still feel impossible.

Denise O'Leary, Clinical Director at Jintara, describes what her team prepares clients for in early detox: "They're going to be going, 'Oh, geez, Louise, that's not as bad as I thought.' Relief. And little do they know that the misery comes later. Our job is to kind of prepare them for that."

The practical consequence of this pattern is that clients who start the first week of treatment feeling relatively settled sometimes resist medication or minimise the clinical picture. Jintara's nursing team uses this window to explain what is coming, establish trust, and confirm that the support structure is in place before symptoms peak.

Jintara uses the Clinical Opiate Withdrawal Scale (COWS) to score opioid withdrawal severity at regular intervals throughout detox, with medication adjusted in response to those scores rather than on a fixed dosing schedule. COWS is a validated 11-item scale that measures the objective and subjective signs of opioid withdrawal, giving the nursing team a consistent, comparable picture at each check. SAMHSA's Treatment Improvement Protocols on detoxification confirm score-based medication adjustment as the evidence-based standard for opioid withdrawal management.

In the early days of detox, nurses check COWS scores up to three times daily in clients with elevated readings. As scores fall and the clinical picture stabilises, monitoring shifts to twice daily, then once daily. This is consistent with Lertkhwan Sukpia's description of how nursing care is calibrated: the interval tightens when the score is high and loosens as the client stabilises.

Vital signs are documented alongside every COWS assessment. Nursing staff remain awake on site through every shift. Escalation pathways to Bangkok Hospital Chiang Mai and RAM Hospital are in place for the rare cases where observation alone is insufficient.

Choosing a detox facility from overseas often comes down to a trust question: are the monitoring protocols they describe the ones they actually use? The Healthcare Accreditation Institute, the same national body that accredits Thailand's hospitals, independently assessed Jintara's clinical processes alongside the national drug-treatment authority and the Department of Medical Services. That joint assessment, certificate no. 25/2569, valid from May 2026 to May 2029, is a third-party answer from three government authorities.

Methadone is Jintara's primary opioid detox medication because it is legal in Thailand, clinically effective for a taper-based withdrawal, and when used as a short-term protocol rather than long-term maintenance, carries no dependence risk beyond what the opioid itself has already created. The MedlinePlus overview of opioid misuse and addiction describes methadone as a clinically established medication for managing opioid withdrawal. The confusion around methadone comes from how it is used in certain countries, where people queue outside clinics indefinitely without a plan to taper off. That is a maintenance model. This stigma is strongest in the UK and Australian markets, where street-based maintenance programs have shaped public perception. What Jintara uses is a taper set to the individual's substance, dose, and history, adjusted to their progress and reduced under clinical supervision.

Buprenorphine and Suboxone are not available options at Jintara. Both are illegal to supply in Thailand. If a client arrives with a prescription for Suboxone from their home country, the clinical team will taper them off it rather than allow unsupervised continuation.

For clients who prefer to avoid methadone, a supported cold turkey approach using comfort medications including clonidine and benzodiazepines is available. In practice, the clinical team finds that many who begin unsupported withdrawal choose to switch to a methadone taper within the first few days, when the discomfort at peak intensity becomes the deciding factor.

In the first 24 hours at Jintara, every person in opioid withdrawal meets the attending psychiatrist, completes arrival nursing assessments, and begins a medical detox plan built around their specific substance history, dose, and current withdrawal status. The intake process is thorough by design: a breath alcohol reading, urine drug screen, and initial COWS scoring give the nursing team an immediate clinical picture, while the psychiatrist meeting produces the medication plan.

Lertkhwan Sukpia, Jintara's Head Nurse, describes the handover from intake to overnight care: the team identifies which clients need close observation and which are stable, confirms medication timing, and walks every client through what the next several days will look like. The first night is managed with reassurance, regular checks, and a clear protocol for escalation.

From the first day, clients are informed about the timeline: what withdrawal will feel like at each stage, when to expect the worst, and how the nursing team will respond. Education about the process reduces fear, and reduced fear reduces the physiological stress response that amplifies withdrawal symptoms.

On the second day of every admission, Jintara takes each client to Bangkok Hospital Chiang Mai or RAM Hospital for a full medical assessment at no additional cost to the client. The workup includes a full blood spectrum, liver function test, kidney function test, EKG, and chest X-ray.

For people withdrawing from opioids, this workup is particularly relevant. Long-term opioid use affects liver function, cardiovascular health, and immune status in ways that may not be obvious on arrival. Identifying abnormal results on day two allows the clinical team to adjust the detox protocol before those findings become complications. In cases of IV drug use, infectious disease screening is added to the standard panel.

The full cost of this assessment is included in the program pricing. There is no separate billing for the hospital visit, the psychiatric assessment on arrival, or the nursing care throughout detox. This is a deliberate part of Jintara's model: no hidden costs in the middle of a medical process is a clinical principle, not just a commercial one.

The type of opioid, how long it has been used, and the daily dose all determine how Jintara's psychiatrist designs the detox protocol. Heroin produces withdrawal symptoms within 12 to 24 hours of the last dose. Prescription opioids such as oxycodone and codeine typically take 24 to 36 hours before symptoms appear, and the overall arc is longer. For fentanyl addiction specifically, the picture is most complex: according to NIDA's fentanyl overview, fentanyl is 50 to 100 times more potent than morphine and accumulates in body tissue, which may extend the clearance timeline considerably beyond what heroin or short-acting opioids require.

The contamination of street supplies with fentanyl has added a layer of uncertainty for clients who believe they have been using heroin or prescription tablets. Many arrive not knowing exactly what they have been taking, and it is this hidden potency that drives the overdose danger of contaminated fentanyl the clinical team screens for on arrival. The clinical response to this is a conservative approach: start with a protocol calibrated for a potent opioid, observe, and adjust based on what the COWS scores and clinical presentation reveal.

Polysubstance use involving opioids alongside alcohol or benzodiazepines creates additional complexity. In these cases, the team manages the most medically dangerous withdrawal pathway first. For dual diagnosis treatment needs arising from underlying anxiety, trauma, or mood disorders, the clinical team addresses these alongside the physical detox.